Physician Education: Bridging Clinical Research and Patient Care

TAM Posttest

Continuing Medical Education Posttest

The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:

July/August 2017, Volume 25, Issue 3

Overview

  • CME Credit Available: 3.25 AMA PRA Category 1 Credits
  • Release Date: August 16, 2017
  • Expiration Date: August 16, 2018

To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.

Learning Objectives

On completion of this activity, the learner will be able to:

  • Describe neurologic complications in persons with HIV disease
  • Describe how viral resistance to direct-acting antiviral drugs may impact their effectiveness during treatment of hepatitis C virus (HCV) disease
  • Identify barriers to treatment for chronic HCV disease
  • Describe the sustained off-treatment response after discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg-sero¬negative persons with hepatitis B disease

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and HCV infections.

Intended Audience

This enduring material is designed for physicians and other health care practitioners who are actively involved in the medical care of people with HIV and HCV infections.

This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

CME Information

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from August 16, 2017, to August 16, 2018. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.

Disclosure of Financial Interests

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, authors, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Dr Kolson has no relevant financial affiliations to disclose. (Updated 08/01/2017)

Dr Luetkemeyer has received research grants awarded to her institution from AbbVie, Gilead Sciences, Inc, and Merck. (Updated 07/14/17)

Dr Wyles has received research grants awarded to his institution from and has served as a consultant or advisor to AbbVie, Gilead Sciences, Inc, and Merck. (Updated 08/07/17)

Dr Scott has served on a data and safety monitoring board for Novartis. He has received research grants for HCV-related research awarded to his institution from Merck. (Updated 06/23/17)

Dr Aronsohn has no relevant financial affiliations to disclose. (Updated 06/23/17)

Dr Duchin has no relevant financial affiliations to disclose. (Updated 06/23/17)

Dr Irvin has no relevant financial affiliations to disclose. (Updated 06/23/17)

Dr Kaufmann has no relevant financial affiliations to disclose. (Updated 06/23/17)

Dr Millman has no relevant financial affiliations to disclose. (Updated 06/23/17)

Dr Vellozzi has no relevant financial affiliations to disclose. (Updated 06/23/17)

Ms Kaufmann has no relevant financial affiliations to disclose. (Updated 06/23/17)

Ms Ntiri-Reid has no relevant financial affiliations to disclose. (Updated 06/23/17)

Dr Muche has received direct travel support from Bristol-Myers Squibb (BMS) and Gilead Sciences, Inc. She also has received direct payment for lectures from BMS. (Updated 07/13/17)

Dr Meyer has no relevant financial affiliations to disclose. (Updated 07/13/17)

Dr Siegmund received consulting or advising fees awarded to her institution from AbbVie, Takeda, Janssen Pharmaceuticals, Falk Foundation, and Merck Sharp & Dohme (MSD). She has received grants awarded to her institution from Hospira. She has received payments for lectures awarded to her institution from AbbVie, Falk Foundation, Ferring Pharmaceuticals, Janssen Pharmaceuticals, Takeda, Biogen, and MSD. (Updated 07/13/17)

Dr Somasundaram has received consulting or advising fees and payments for lectures awarded to his institution from MSD. (Updated 07/13/17)

Dr Epple has no relevant financial affiliations to disclose. (Updated 07/13/17)

Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, Merck, and Monogram Biosciences, Inc. (Updated 05/24/17)

Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to her institution from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. Her spouse, Robert T. Schooley, MD, serves as a consultant to CytoDyn and Antiva Biosciences. He is a stockholder of Antiva Biosciences and has stock options from CytoDyn. He serves as a Scientific Advisory Board Member (honoraria remitted to the University of California) for Gilead Sciences, Inc, and LabCorps. (Updated 05/22/17)

Dr Hirsch has no relevant financial affiliations to disclose. (Updated 08/15/17)

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 08/16/17)

The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

Independent educational grants for the 2017 Improving the Management of HIV Disease® CME program:

PLATINUM SUPPORTER
ViiV Healthcare

GOLD SUPPORTER
Gilead Sciences, Inc

SILVER SUPPORTERS
Bristol-Myers Squibb
Janssen Therapeutics

BRONZE SUPPORTER
Merck

Independent educational grants for the 2017 Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes CME program:

GOLD SUPPORTERS
Gilead Sciences, Inc
Merck

BRONZE SUPPORTER
AbbVie

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.

Contact Information

If you have any questions about this activity, please contact the IAS–USA:

E-mail: journal“at”iasusa.org
Mail: 425 California Street, Suite 1450, San Francisco, CA 94104-2120
Phone: 415-544-9400
Fax: 415-544-9401

By clicking “Begin,” I acknowledge that I have read these instructions and understand them.

You must log in to take the activity.

Begin